Rejuvenate Biomed to accelerate its drug development pipeline
of assets for age-related diseases using jointly developed
tools
DIEPENBEEK, Belgium and CARY,
N.C., Aug. 1, 2024 /PRNewswire/ -- Rejuvenate
Biomed and SAS announced today a partnership to develop a
user-friendly drug repurposing discovery tool for researchers and
scientists to uncover medically relevant insights about drugs,
diseases, and biological networks, through fast and systematic
explorations of hidden biological patterns. The discovery tool will
be developed on SAS® Viya®, a powerful
cloud-native artificial intelligence (AI) and data platform. The
partnership will unite Rejuvenate Biomed's clinically validated
AI-driven drug discovery platform and end-to-end drug development
proficiency with SAS' decades of AI expertise.
Rejuvenate Biomed's drug discovery tool
will be developed on SAS Viya, a powerful cloud-native AI &
data platform.
The comprehensive low-code tool will take data from known
biomedical relationships and use SAS-based analytics to implement
algorithms to uncover non-trivial and novel biological
interactions, tapping SAS Visual Analytics for report
creation. Aimed at ease of use, the tool will cater to bioscience
researchers with limited coding experience, while also serving as a
foundation for advanced analytics model development for
cutting-edge computational biology teams.
In addition, the collaboration between the two companies equips
Rejuvenate Biomed with the tools and technology necessary to
further develop and scale up its drug discovery platform, third
party services and drug development pipeline.
"Our partnership with SAS amplifies the core strengths of both
our R&D teams," Dr. Ann Beliën, Founder and Chief Executive
Officer of Rejuvenate Biomed. "By embracing this partnership and
leveraging the capabilities of SAS Viya, we expect to meaningfully
de-risk and accelerate the development of our internal portfolio
while enhancing our discovery platform and partnering
capabilities."
"Our collaboration with Rejuvenate Biomed places us at the
forefront of AI in biomedical research, reinforcing our commitment
to supporting cutting-edge applied AI and analytics through SAS
Viya," said Udo Sglavo, Vice
President of Applied AI and Modeling at SAS. "Rejuvenate Biomed's
endorsement of SAS Viya to further develop their unique and
proprietary drug discovery engine is a testament to our commitment
to being the premier provider of structured and scalable AI
solutions that enhance data analysis efficiency and accelerate the
entire drug development life cycle."
About Rejuvenate Biomed
Rejuvenate Biomed is a
clinical-stage biotechnology company developing therapeutics that
target the root causes of age-related diseases. Utilizing two
clinically validated proprietary drug discovery platforms,
the AI-enabled in
silico CombinAgeTM and in
vivo CelegAgeTM, Rejuvenate Biomed has built a
pipeline of five unique combination drugs targeting different
age-related diseases, including neuromuscular, musculoskeletal,
metabolic, cardiovascular, nephrological, and neurodegenerative
indications. Its lead Phase 2-ready asset, RJx-01, has
already demonstrated significant potential in treating sarcopenia.
The company's disease agnostic drug discovery platforms continue to
provide insight into future therapeutics, driving pipeline growth
and potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to
promoting healthy aging.
For more information, please visit
https://www.rejuvenatebiomed.com/en or
contact: communications@rejuvenatebiomed.com
About SAS
SAS is a global leader in data and AI. With SAS software and
industry-specific solutions, organizations transform data into
trusted decisions. SAS gives you THE POWER TO KNOW®.
Rejuvenate Biomed Contacts
Company contact
communications@rejuvenatebiomed.com
Media Contact
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
SAS Contacts
Jennifer James
SAS Media Relations
Jennifer.james@sas.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rejuvenate-biomed-and-sas-tap-ai-to-develop-disease-agnostic-drug-repurposing-discovery-tools-302212040.html
SOURCE SAS